Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program
Sarah L Osborne, Sepehr N Tabrizi, Julia ML Brotherton, Alyssa M Cornall, John D Wark, C David Wrede, Yasmin Jayasinghe, Dorota M Gertig, Marian K Pitts, Suzanne M Garland
Vaccine | ELSEVIER SCI LTD | Published : 2015
We gratefully acknowledge the Victorian Cancer Agency as our funding body. We thank Elisa Young for initial project management and co-ordination and Adele Rivers for participant recruitment and management. We also acknowledge Houda Abdo and Angela Hurley for completing all HPV genotyping analysis and Athena Costa for assisting with the manuscript submission. We thank the NHVPR staff who assisted with the study, particularly Daniela Petrovski and Jennifer Nguyen. The NHVPR is owned by the Australian Government Department of Health and operated by the VCS.Conflict of interest statement: SMG has received advisory board fees and grant support from CSL and GlaxSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, S.M.G. has received funding to conduct HPV vaccine studies for MSD and GSK. S.M.G. is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. JMLB, DMG MS and SMG were partner investigators on an Australian Research Council Linkage Grant 2008-2011 on which CSL Biotherapies was a partner organisation. S.M.G., S.N.T., J.M.L.B. are partner investigators with CSL Biotherapies for a cervical cancer genotyping study.